ArticleRheumatology (Oxford, England)2026
Prolonged serologically active clinically quiescent systemic lupus erythematosus: a longitudinal study on the role of IgG anti-dsDNA and C3.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess whether fluctuations in immunoglobulin G anti-double stranded DNA (IgG anti-dsDNA) antibodies and C3 levels predict flares and sustained activity in patients with prolonged serologically active clinically quiescent (SACQ) systemic lupus erythematosus (SLE), and to explore additional risk factors for flare.
methodsSLE patient data from the University College London Hospital Lupus cohort were collected (2020-2025). Prolonged SACQ was defined as ≥6 months of elevated IgG anti-dsDNA and/or low C3 without clinical activity (BILAG-2004 index D/E in all domains). Associations between biomarker changes and outcomes, adjusted for main confounders, were tested longitudinally with generalized estimating equations (GEE).
resultsSixty patients (531 visits) were included. Over a mean 3.3-year follow-up, 38 patients (63.3%) experienced ≥1 flare. Baseline characteristics were comparable between patients with and without flares, except for longer follow-up duration (P = 0.005) and a higher prevalence of anti-Ro positivity (P = 0.018) among those who developed flares. In GEE-models, higher IgG anti-dsDNA and lower C3 levels independently predicted flares and sustained activity at the subsequent visit, including moderate-to-severe cases.
conclusionMost SACQ patients developed clinical flares. Changes in IgG anti-dsDNA and C3 levels emerged as strong predictors of flare in prolonged SACQ patients in a visit-by-visit analysis, supporting close clinical monitoring and highlighting the value of serological trends despite the presence of prolonged clinical quiescence and sustained biomarker abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.